Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 89OTHER 88NETWORK 3OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × ribociclib × Clear all
NCT07391774 2026-06-05

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡